Kerzel C, Keller P J
CIBA-GEIGY AG, Basel.
Geburtshilfe Frauenheilkd. 1987 Aug;47(8):565-8. doi: 10.1055/s-2008-1035876.
In an open study 112 women with menopausal symptoms were treated with a transdermal therapeutic system delivering estradiol at a rate of 25, 50 or 100 micrograms per day resp. The study, which was to measure the therapeutic efficacy and systemic and local tolerability, lasted 3 months. At the end of the treatment period 46% of the women were completely free of symptoms and a further 46% very much improved. In 64% the hot flushes disappeared entirely and in the remaining women their frequency and intensity, with a few exceptions, were markedly diminished. Nocturnal bouts of sweating were completely prevented in 67% of those complaining of this symptom. Pollakiuria improved in 93%. Before commencement of the therapy 24 patients felt unwell; during the study only two. The proportion of women who felt well or very well rose from 36% to 83%. The systemic tolerability was rated good or excellent by 97% of patients and in no case was it rated poor. Blood pressure and body weight were not affected. The local tolerability was considered good or very good by 80% of the women; it was poor in 5 cases (4.6%) and only in one case did it lead to discontinuation of the therapy. Ninety percent of the participants wanted to continue treatment beyond the duration of the study.
在一项开放性研究中，112名有更年期症状的女性接受了一种经皮治疗系统的治疗，该系统分别以每天25微克、50微克或100微克的速率释放雌二醇。这项旨在测量治疗效果以及全身和局部耐受性的研究持续了3个月。在治疗期结束时，46%的女性症状完全消失，另有46%有很大改善。64%的女性潮热完全消失，其余女性的潮热频率和强度（少数例外情况除外）明显降低。67%主诉有夜间盗汗症状的女性夜间盗汗完全得到预防。尿频改善率为93%。治疗开始前有24名患者感觉不适；研究期间只有2名。感觉良好或非常良好的女性比例从36%升至83%。97%的患者对全身耐受性的评价为良好或极佳，无一例评价为差。血压和体重未受影响。80%的女性认为局部耐受性良好或非常良好；5例（4.6%）较差，只有1例导致治疗中断。90%的参与者希望在研究期结束后继续接受治疗。
